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The impact of serotonergic neurotransmission on brain dopaminergic pathways has substantial relevance to many neuropsychiatric
disorders. A particularly prominent role has been ascribed to the inhibitory effects of serotonin 2C receptor (5-HT2CR) activation on
physiology and behavior mediated by the mesolimbic dopaminergic pathway, particularly in the terminal region of the nucleus accum-
bens. The influenceof this receptor subtypeon functionsmediatedby thenigrostriatal dopaminergic pathway is less clear.Herewe report
that a null mutation eliminating expression of 5-HT2CRs produces marked alterations in the activity and functional output of this
pathway. 5-HT2CR mutant mice displayed increased activity of substantia nigra pars compacta (SNc) dopaminergic neurons, elevated
baseline extracellular dopamine concentrations in the dorsal striatum (DSt), alterations in grooming behavior, and enhanced sensitivity
to the stereotypic behavioral effects of D-amphetamine and GBR 12909. These psychostimulant responses occurred in the absence of
phenotypic differences in drug-induced extracellular dopamine concentration, suggesting a phenotypic alteration in behavioral re-
sponses to released dopamine. This was further suggested by enhanced behavioral responses of mutant mice to the D1 receptor agonist
SKF 81297. Differences in DSt D1 or D2 receptor expressionwere not found, nor were differences inmedium spiny neuron firing patterns
or intrinsic membrane properties following dopamine stimulation. We conclude that 5-HT2CRs regulate nigrostriatal dopaminergic
activity and function both at SNc dopaminergic neurons and at a locus downstream of the DSt.
Introduction
The prominence of central serotonin (5-HT) and dopamine
(DA) systems in the pathophysiology and treatment of neuropsy-
chiatric disorders underscores the importance of understanding
how these systems interact. It is established that the serotonin
system regulates themesoaccumbal andnigrostriatal dopaminer-
gic pathways (Esposito, 2006; Alex and Pehek, 2007; Fink and
Go¨thert, 2007). Serotonergic cell bodies in the raphe nuclei
project to the substantia nigra pars compacta (SNc) and ventral
tegmental area (VTA) and their terminal projections within the
dorsal striatum (DSt) and nucleus accumbens (NAc), respec-
tively (Bobillier et al., 1975; Fibiger andMiller, 1977; Herve´ et al.,
1987;Nedergaard et al., 1988). The serotonin system regulates the
functional output of these pathways, but precise mechanisms
remain to be clarified (Kelland et al., 1990, 1993; De Deurwaer-
de`re et al., 1996; Saito et al., 1996).
Among the 14 serotonin receptor subtypes, the serotonin 2C
receptor (5-HT2CR) is believed to play a particularly prominent
role in the modulation of dopamine function (Di Matteo et al.,
2002b; Esposito, 2006). 5-HT2CRmRNA is abundantly expressed
on GABAergic neurons within the SNc and VTA and in the DSt
and NAc (Mengod et al., 1990; Ward and Dorsa, 1996; Eberle-
Wang et al., 1997). 5-HT2CRs are implicated in tonic and phasic
modulation of the mesoaccumbal dopamine pathway. Pharma-
cological activation of 5-HT2CRs inhibits firing rates of VTAneu-
rons and DA release within the NAc (Prisco et al., 1994; Di Mat-
teo et al., 1998; Di Giovanni et al., 1999).
How 5-HT2CRs participate in the regulation of nigrostriatal
DA system function is less clear. It has been suggested that
5-HT2CRs have less influence on the nigrostriatal than on the
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mesoaccumbalDApathway (DiMatteo et al., 2001). This is based
on reports that pharmacological manipulations of 5-HT2CRs
produce relatively modest effects on SNc dopaminergic neuronal
activity andDA release in the DSt (Kelland et al., 1990; DiMatteo
et al., 1999; Di Giovanni et al., 2000). However, other studies
indicate that 5-HT2CR agonist and antagonist treatments impact
DA release in the DSt and NAc in a similar manner (De Deur-
waerde`re and Spampinato, 1999; Gobert et al., 2000; Porras et al.,
2002; De Deurwaerde`re et al., 2004; Navailles et al., 2004). These
conflicting results may be attributable to the use of different
5-HT2CR ligands with varying specificity and modes of action.
It is possible that the impact of 5-HT2CR function on behav-
iors regulated by the nigrostriatal DA system may occur through
the actions of these receptors within the SNc. However,
5-HT2CRs are also expressed in a number of basal ganglia struc-
tures to which the DSt projects (Wright et al., 1995; Eberle-Wang
et al., 1997). 5-HT2CRs expressed in basal ganglia structures out-
side the DSt have previously been implicated in movement dis-
orders such as oral dyskinesias (Eberle-Wang et al., 1996).
Here, we use a genetic approach to investigate the role of
5-HT2CRs in physiology and behaviors associated with nigrostri-
atal dopamine pathway function. This was pursued in studies of
mice bearing a null mutation of the htr2c gene by a combination
of electrophysiological, pharmacological, neurochemical, and
behavioral approaches.
Materials andMethods
Animals. Mice were produced in our rodent colony (5-HT2CR mutant
and littermate wild-type controls) or were purchased from The Jackson
Laboratory (wild-type C57BL/6J mice). The generation of 5-HT2CR null
mutant mice has been described in detail previously (Tecott et al., 1995).
The htr2cmutation is congenic on a C57BL/6J background and main-
tained by mating 5-HT2CR heterozygous females and C57BL/6J males.
Animals were weaned at 3 weeks and group housed in standard polypro-
pylene cages (16 27 12 cm) with 3–5 littermates per cage. Mice had
ad libitum access to water and chow (PicoLab Mouse Diet 20, Purina
Mills). The housing facility was maintained at 22°C with a 12-h-on/12-
h-off lighting schedule, lights on at 7:00 A.M.Unless otherwise indicated,
these studies used male mice 2.5–4 months old.
Drugs. GBR 12909 (a selective inhibitor of the dopamine reuptake
transporter, Sigma-Aldrich; Tocris Bioscience) was dissolved by gentle
heating and sonication. Animals received GBR 12909 doses of 0, 3, 10,
and 30 mg/kg. SB 206553 (a 5-HT2CR inverse agonist, Sigma-Aldrich) at
doses of 0 and 5mg/kgwere similarly prepared. D-Amphetamine (Sigma-
Aldrich) was used at doses of 0, 2.5, 5, and 10 mg/kg. Quinpirole (a
selective D2 receptor agonist, Tocris Bioscience) was administered at
doses of 0, 0.6, 2, and 6mg/kg. SKF 81297 (a selectiveD1 receptor agonist,
Tocris Bioscience) was administered at 0 and 10mg/kg. All mice received
intraperitoneal doses of drug in 10 l/g injection volumes. All vehicles
used in these studies were normal saline.
Single-cell recording procedures.Mice (n 8 wild type, n 8 5-HT2CR
mutant) were anesthetized with chloral hydrate (400 mg/kg, i.p.) and
mounted on a stereotaxic apparatus (SR-6, Narishige). Body tempera-
turewasmaintained at 36–37°C. A 28 gauge needle was placed in a lateral
tail vein through which additional anesthetic was administered as re-
quired. The skull overlying both the SNc and the VTAwas removed. The
coordinates (relative to the interaural line) for recording electrode place-
ment were as follows: SNc, anteroposterior (AP) 0.16–0.72 mm,medio-
lateral (ML) 1.1–1.5 mm, dorsoventral (DV) 3.8–4.8 mm; VTA, AP
0.16–0.72 mm, ML 0.1–0.5 mm, DV 3.8–4.8 mm (Paxinos and Frank-
lin, 2001). Extracellular recordings were obtained using single-barrel mi-
cropipettes (4–7 M resistance containing 2% pontamine sky blue dye
in 2 M NaCl). DA neurons were identified by standard electrophysiolog-
ical criteria (Bunney et al., 1973; Grace and Bunney, 1980; Wang, 1981;
Sanghera et al., 1984). Spike activity was detected using a high-
impedance amplifier connected to an analog oscilloscope, audio moni-
tor, and window discriminator. Unit activity was converted to an inte-
grated histogram by a rate-averaging algorithm and displayed as spikes
per 10 s intervals. The basal electrical activity of each DA neuron was
recorded for at least 5 min to establish the baseline firing rate and burst-
ing activity. The number of spontaneously active DA neurons within
both the SNc and the VTA regions were counted by lowering the elec-
trode through a block of tissue, which could be reproducibly located
from animal to animal. Twelve electrode tracks (separated from each
other by 200 m), whose sequence was kept constant from animal to
animal, were made in each region. Only cells whose electrophysiological
characteristics matched those previously established for midbrain DA
neurons were sampled. After each experiment, the recording site was
marked by injection of pontamine sky blue dye using a20 A current
for 10min. Brainswere removed andplaced in 10%buffered formalin for
2 d before histological examination. Frozen sections were cut at 40 m
intervals and stained with neutral red. Microscopic examination of the
sections was performed to verify that the electrode tip was in the SNc or
the VTA.
Single-cell recording data analysis. The mean number of cells per track
was calculated by dividing the total number of DA neurons encountered
by the total number of electrode tracks performed for either the SNc or
the VTA. Burst analysis of DA neurons was performed using RISI (Sym-
bolic Logic). A total of 500–1200 consecutive spikes were recorded for
each neuron in both wild-type and mutant mice. Burst firing, when
present, was detected using an algorithm similar to that previously de-
scribed (Grace and Bunney, 1984). Themean percentage of spikes occur-
ring in bursts was used as a measure of bursting activity. Differences in
the number of cells per track, the basal firing rate, and the bursting
activity between wild-type andmutant mice were analyzed by two-tailed
Student’s t test. All statistical analyses were performed with StatView
version 5.0.1 (SAS Institute).
Microdialysis probe construction and implantation. Probe implantation
occurred 12–48 h before dialysis testing. Concentric microdialysis
probes consisted of 23 gauge stainless steel and silica capillary tubing. The
dialysis membrane (inner diameter 240 m, outer diameter 290 m, 2
mm exposed for striatum, 1 mm exposed for NAc, AN 69HF, Hospal)
consisted of polyacrylonitrile/sodium methylsulfonate copolymer with
an average pore size of 29 Å. Mice were anesthetized using inhalational
(isoflurane or halothane, 2%, 800 ml/min O2) or injectable (ketamine
100 mg/kg–xylazine 10 mg/kg, i.p.) agents. Lidocaine was used for local
anesthesia. The animals were placed in a stereotaxic frame (Kopf Instru-
ments), and probes were inserted into the striatum (0.7 AP,2.0 ML,
3.0 DV for standardmicrodialysis;0.5 AP,2.0ML,5.0 DV for no
net fluxmicrodialysis) orNAc (1.5 AP,0.8ML,5.3DV, only no net
fluxmicrodialysis) per established atlas coordinates (Paxinos and Frank-
lin, 2001). Probes were secured to the skull using dental cement. Mice
were then returned to a standard polycarbonate cage with sawdust bed-
ding and allowed to regain consciousness.
Standardmicrodialysis procedure. Experiments were performed 24–48
h after surgery. On the day of the experiment, the microdialysis probes
were connected with flexible PEEK tubing to a microperfusion pump
(Harvard Apparatus, PHD 2000) and perfused with artificial CSF
(aCSF), containing 146mMNaCl, 2.9mMKCl, 1.2mMCaCl2, and 1.1mM
MgCl2, at a flow rate of 1.0–1.5 l/min (for GBR 12909 microdialysis
experiments, aCSF also contained 2 mM Na2HPO4, pH 7.40). Microdi-
alysis samples were collected at 15–20 min intervals into vials (for GBR
12909 study, containing 7.5 l of 0.02 M formic acid). Microdialysis
samples were collected by an automated fraction collector (Univentor
820) and stored at 80°C. Drug treatment (either D-amphetamine or
GBR 12909) was administered immediately before collection of the sixth
sample. After the experiment, mice were killed and their brains removed
and incubated for 3 d in 4% paraformaldehyde. The probe position was
histologically verified in coronal brain sections (Paxinos and Franklin,
2001).
No net flux microdialysis procedure. aCSF consisted of 149 mM NaCl,
2.8mMKCl, 1.2mMCaCl2, 1.2mMMgCl2, 0.25mM ascorbic acid, and 5.4
mM D-glucose, pH 7.3. Perfusate flow rate to both probes was 0.2l/min
for the first 10 postsurgical hours, and then increased to 0.6 l/min 1 h
before the start of dialysate collection and for the remainder of the ex-
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periment. Following equilibration, six baseline samples were collected at
10min intervals. The perfusatewas switched to aCSF containing 5 nMDA
and allowed to equilibrate for 30 min followed by dialysate collection for
30 min. This same procedure was subsequently used for perfusates con-
taining 10 and 20 nM dopamine. Following collection, dialysate samples
were immediately frozen and stored at70°C.
DA measurements. Dialysate aliquots were injected onto a reversed
phase column (3 m C18 stationary phase, multiple vendors). Samples
were eluted with a mobile phase (acetonitrile, phosphate buffer, and an
ion-pairing agent, ESA) for D-amphetamine studies; NaAc buffer (4.1
g/L) withMeOH (2.5% v/v), Titriplex (150mg/L), OSA (150mg/L), and
TMACl (150 mg/L, pH 4.1) for GBR 12909 studies, and 17% acetonitrile
(v/v) in a 25mMNaH2PO4 buffer containing 0.1 mMNa2-EDTA, 1.6 mM
1-decanesulfonic acid, and 14.4mM triethylamine, pH 3.9, for no net flux
studies. Pump flow rates were 0.25 ml/min, 0.35 ml/min, and 35 l/min
for D-amphetamine, GBR 12909, and no net flux studies, respectively.
For D-amphetamine studies,DAwas detected using an amperometric cell
(Model 5041, ESA) at a potential of175 mV coupled to a coulometric
detector (Coulochem II, ESA). For GBR 12909 studies, DA was detected
using a glassy carbon electrode at a potential of 500 mV (vs Ag/AgCl
reference electrode) coupled to an Intro detector (Antec Leyden). For no
net flux studies, DA was detected using a glassy carbon electrode at a
potential of700 mV (vs Ag/AgCl reference electrode) as controlled by
an amperometric detector (EG&G 400, Princeton Applied Research).
On-column limits of quantification were 2 fmol (D-amphetamine), 0.3
fmol (GBR 12909), and 0.5 fmol (no net flux).
For D-amphetamine and GBR 12909 studies, basal DA levels were
defined as the average of the first five samples. To determine the effect of
genotype on DA release after treatment, repeated-measures ANOVAs
were performed on values obtained during the 180 min following drug
injection (time intervals 6–14).
Syntactic grooming studies. Syntactic grooming chains (as described by
Aldridge and Berridge, 1998) were observed in cohorts of 2–3-month-
old male mice (n 9 wild type, n 8 mutant) following gentle misting
of their back flanks with room temperature tap water. Mouse grooming
activity was videotaped from two directions for 10 min. All mice were
tested for 10 consecutive days between 1:00 and 4:00 P.M. daily. Groom-
ing videos were digitized toMPEG, and scored by a single investigator in
a blinded manner using Observer Video-Pro 5.0 (Noldus). At least 15
min of total grooming time was evaluated for each mouse. As described,
completed syntactic chains could have multiple morphologies, but all
chains had to begin in phase 1, be followed by either phase 2, phase 3, or
phase 2–phase 3, and then end with phase 4. Incomplete chains always
began with phase 1, but did not evolve according to the above criteria.
Nonsyntactic grooming states were scored for all grooming behavior not
classified as either a completed or broken syntactic chain. Differences in
grooming behavior properties were evaluated by Student’s t test with p
values adjusted for multiple comparisons using Bonferroni corrections.
Locomotor activity monitoring. Animals were singly housed in 16 stan-
dard polypropylene cages (45  24  17 cm) surrounded by 8  4
photobeam activity monitoring brackets (FlexField, San Diego Instru-
ments). Bedding was placed on the cage floor; food and water were pro-
vided ad libitum. Mice were acclimated to these home cages for 4–5 d
before drug administration. Mice received intraperitoneal injections of
saline vehicle between 1:00 and 3:00 P.M. each day before drug admin-
istration to habituate them to injections. At each treatment dose,
repeated-measures ANOVA was conducted on values between 0 and 90
min after the injection with time as a within-subject factor and genotype
and treatment as between-subject factors. In addition, univariate
ANOVA was conducted on peak locomotor activity (LA) with genotype
and treatment as between-subject factors.
Stereotypic behavior measurement. The same habituation protocol for
LAwas followed. Home cage behavior was video recorded for 3–4min at
intervals chosen based onobservations frompilot studies. These intervals
were 30 and 90 min after GBR 12909 and GBR 12909/SB 206553 injec-
tion, 30 and 75 min after 2.5 and 5 mg/kg D-amphetamine injection, and
30 and 110min after 10mg/kg D-amphetamine injection. For SKF 81297
and quinpirole treatments, mice were videotaped for 10 min (10 min
after drug injection). Videotaped behavior trials were converted to digital
video and scored for stereotypy. Differences in motor and stereotypy
responses betweenGBR12909 and D-amphetamine have previously been
noted (Hooks et al., 1994); we thus used stereotypy rating scales appro-
priate for each treatment. Motor stereotypy in response to GBR 12909
treatment was scored using a modified version of a previously published
protocol (Creese and Iversen, 1973). Six distinct behaviors were noted:
asleep (score 1), awake inactive (score 2), awake locomotion (score 3),
awake “route tracing” locomotion (score 4), intermittent oral/grooming
stereotypies (score 5), and continuous oral/grooming stereotypies (score
6). Motor stereotypy in response to D-amphetamine treatment was
scored using a modified version of a previously published protocol
(Chartoff et al., 2001). Eight distinct behaviors were noted: no move-
ment, ambulation, oral stereotypy, sniffing, rearing, vigorous grooming,
taffy pulling, and climbing. For both GBR 12909 and D-amphetamine
treatment, behaviors were scored at the start and every 10 s into the trial.
For SKF 81297 and quinpirole treatments, videos were scored for the
entire 10 min recording period. Investigators were blinded to genotype
and drug treatment status. For each treatment dose, repeated-measures
ANOVA was conducted with time as a within-subject factor and geno-
type and treatment as between-subject factors.
Slice preparation and electrophysiology.Male P22-P28 mice were anes-
thetized with halothane and decapitated, the brain was rapidly removed,
and coronal slices (300 m) were cut in 4°C aCSF using a VT1000S
(Leica). Slices were recovered at 32°C in carbogen-bubbled aCSF (126
mMNaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 1.2 mMMgCl2, 2.4 mM CaCl2,
18 mM NaHCO3, and 11 mM glucose, with pH 7.2–7.4, 301–305 mOsm)
for 30 min to 5 h. During experiments, slices were submerged and con-
tinuously perfused (using a peristaltic pump, 2 ml/min) with
carbogen-bubbled aCSF warmed to 31–32°C and supplemented with
CNQX (10 M, to block AMPA-type glutamate miniature EPSPs) and
picrotoxin (50 M, to block GABAA receptors). All reagents were bath
applied.
Whole-cell recordings were made from DSt medium spiny neurons
(MSNs), identified as previously described (Hopf et al., 2003), using a
potassiummethanesulfonate-based internal solution [KOH0.98% (v/v),
methanesulfonic acid 0.76% (v/v), hydrochloric acid 0.18% (v/v), 20mM
HEPES, 0.3mMEGTA, 2.8mMNaCl, 2.5mg/mlMgATP, and 0.25mg/ml
GTP, pH 7.2–7.4, 275–285 mOsm]. Current pulses were applied using
Clampex 9.2 and 700A patch amplifier in current-clamp mode (Molec-
ular Devices). Series resistance correction was 15–25 M. The resting
membrane potential was determined just after breaking into a neuron,
and each neuron was then brought to a resting potential of approxi-
mately80 mV by passage of DC current via the patch amplifier before
collection of firing data.
To generate action potentials, neurons in current clampwere depolar-
ized with a series of seven or eight 300 ms current pulses, with 20 pA
between each current step, where the initial current step for each neuron
was just subthreshold for firing. This series of current pulses was deliv-
ered every 30 s, alternating with a 33.3 pA hyperpolarizing pulse. Patch-
clamp data were collected at 15 kHz and filtered at 2 kHz. All data were
analyzed using Clampfit (Axon Instruments). To calculate percentage
change in spiking, a current pulse was selected that exhibited two spikes
at baseline, or three spikes if no current step evoked two spikes. The same
current pulse was used for time points before and after drug addition.
Spike firing rates during the 3 min before addition of the reagent were
averaged and this value normalized to 100%. Statistical significance was
determined for the average spike firing change during the last 2 min of
exposure to reagents All statistics were performed using a two-tailed,
unpaired Student’s t test.
Receptor autoradiography. Mice underwent rapid decapitation, brain
dissection, and tissue freezing on powdered dry ice. Coronal sections (20
m thickness) were cut on a cryostat with appropriate histological refer-
ence slides and stored desiccated at 20° until ready for tissue process-
ing. All radioligand binding reactions occurred within 1 week of cutting
the sections. Sections were preincubated in buffer (50 mM Tris-HCl, pH
7.4, 120mMNaCl, 5mMKCl, 2mMCaCl2, 1mMMgCl2, and either 40 nM
ketanserin (to block nonspecific 5-HT2A and 5-HT2C receptor binding in
the D1 reaction) or 0.5MDTG, 0.1M pindolol (to block nonspecific 
and 5-HT1AR receptor binding in the D2 reaction) for 1 h before indirect
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or direct radioligand binding. 3H-SCH23390 at 13.2 nMwas used to assay
for D1 receptors (run with an excess of cis-flupenthixol in the indirect
reaction); 3H-YM-09151–2 at 17 M was used to assay for D2 receptors
(run with an excess of sulpiride in the indirect reaction). Following 1 h
incubation on ice, sections were washed twice in chilled buffer, rinsed in
chilled distilled water, and then gently dried with hot air. Sections were
processed by investigators blinded to genotype and were stratified such
that sections cut at similar levels were processed in the same batch. Slides
were then placed in autoradiography cassettes reserved for tritium use,
tritiated standards were placed with each film, and exposures were taken
at 4°C for 4 weeks onto Kodak tritium hyperfilm. Films were developed
by hand, scanned to computer, and analyzed using the public domain
NIH Image program (developed at the United States National Institutes
of Health and available at http://rsb.info.nih.gov/nih-image/). Land-
marks for theDSt andNAcwere taken from a standardmouse brain atlas
(Paxinos and Franklin, 2001).
Results
SNc dopaminergic neurons display increased basal firing
rates and bursting activity in 5-HT2CRmutant mice
Extracellular microelectrode recordings were obtained to assess
how the htr2c mutation influenced baseline electrophysiologi-
cal properties of midbrain dopaminergic neurons. No significant
differences in the number of spontaneously active DA neurons
were found between wild-type and mutant mice, either in the
SNc or the VTA (Fig. 1A). At the SNc, statistically significant
increases in dopaminergic neuron tonic firing rate (Fig. 1B) and
percentage bursting activity (Fig. 1C) were noted in 5-HT2CR
mutant mice compared with wild types. Basal activity of SNc DA
neurons in mutant mice increased by 20%, whereas bursting ac-
tivity of these neurons increased by almost
50%. Interspike interval histograms re-
vealed a skew toward lower-frequency ac-
tivity in 5-HT2CR mutant mice compared
with wild types (Fig. 1D,E). This probably
occurs as a result of the increased bursting
behavior, leading to an increase in long in-
terspike intervals between the bursts, al-
though the mean frequency is increased.
No statistically significant differences in
either basal or percentage bursting activity
were observed between 5-HT2CR mutant
and wild-type mice at the VTA (Fig.
1B,C).
Extracellular dopamine is increased in
the DSt and NAc of 5-HT2CR
mutant mice
To determine whether alterations in tonic
and phasic SNc dopaminergic neuron ac-
tivity were reflected at the dopaminergic
terminal fields, we performed no net flux
microdialysis to measure DSt and NAc
baseline extracellular dopamine concen-
trations in awake, behaving mice. Esti-
mates of extracellular DA concentrations
in each brain region were calculated from
the mean of three samples at each perfus-
ate concentration (0, 5, 10, and 20 nMDA).
First-order regressionswere used to obtain
slope and intercept values, which were
solved for the point of no net flux (zero
intercept on the y-axis) (Parsons and Jus-
tice, 1994).
Figure 2, A and C, depicts data where
the microdialysis probe was placed within the DSt. DSt extracel-
lular dopamine concentrations were nearly twice as large in mu-
tantmice comparedwithwild types. Extracellular dopamine con-
centrations in the NAc were modestly increased in mutant mice
compared with wild types (Fig. 2B,C).
Increased syntactic grooming chain failures and altered
grooming behaviors in 5-HT2CRmutant mice
Given the above electrophysiological and neurochemical evi-
dence that 5-HT2CR loss increases nigrostriatal dopaminergic ac-
tivity, we proceeded to determine whether these changes were
accompanied by altered DSt-organized behaviors. One such be-
havior is syntactic grooming.More than 15minof overall groom-
ing activity (pooled over the 10 d of observation) were obtained
for all mice studied. In general, the majority of observed groom-
ing behavior was nonsyntactic. The percentage of grooming ac-
tivity occurring within syntactic chains (5%, total observation)
was similar to that reported by other groups (Aldridge and Ber-
ridge, 1998). No statistically significant phenotypic differences in
syntactic grooming initiation rate, syntactic grooming frequency,
or latency to first syntactic grooming episode were observed.
However, 5-HT2CRmutantmice spent significantlymore time in
syntactic phase 3 and significantly less time in syntactic phase 4
(Fig. 3A).
5-HT2CRmutant mice also demonstrated gross differences in
nonsyntactic grooming behavior compared with wild-type mice
(Fig. 3B). While there were no significant differences in overall
grooming duration between wild-type and 5-HT2CR mutant
Figure 1. 5-HT2CR mutant mice display increased SNc dopaminergic neuronal activity. A, Numbers of spontaneously active
dopaminergic neurons encountered while recording from SNc and VTA revealed no phenotypic difference. B, 5-HT2CR mutant
mice exhibit increased dopaminergic cell firing in SNc but not in VTA (5.38 0.23 vs 4.49 0.22 spikes/s for SNc, p 0.01;
4.55 0.21 vs 4.60 0.16 spikes/s for VTA, NS). C, 5-HT2CRmutant mice exhibit increased dopaminergic cell burst firing in SNc
but not VTA (16.2 2.5% vs 8.6 1.9% cells bursting for SNc, p 0.05; 16.6 2.5% vs 17.5 2% cells bursting for VTA, NS).
D, E, Interspike interval histograms for SNc neurons recorded fromwild-type (D) and 5-HT2CR mutant (E) mice demonstrate that
SNc neurons from mutant mice have overall higher-frequency activity spike trains than those seen in wild-type mice. Data are
represented as mean SEM. n 8 per genotype. *p 0.05; **p 0.01.
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mice, 5-HT2CR mutant mice had a significantly higher nonsyn-
tactic grooming initiation rate and a correspondingly significant
decrease in nonsyntactic grooming episode duration. No differ-
ences in latency to nonsyntactic grooming episodes were noted.
5-HT2CRmutant mice performmore orofacial motor
stereotypies following D-amphetamine treatment
We evaluated LA and stereotypy responses to D-amphetamine
treatment in wild-type and 5-HT2CR mutant mice. LA in re-
sponse to 2.5, 5, and 10 mg/kg D-amphetamine is depicted in
Figure 4A–C. Characteristic dose- and time-dependent locomo-
tor responses to D-amphetamine were observed. A 2.5 mg/kg
dose of D-amphetamine resulted in a robust locomotor response
that reached peak values at 40 min, then declined, reaching con-
trol values at 110 min after injection (Fig. 4A). After 5 mg/kg
D-amphetamine, locomotion increased more rapidly, peaking 30
min after injection, declining at a slower rate, and finally attaining
baseline values 180 min after injection (Fig. 4B). An early but
smaller peak in locomotion (10min after injection) was observed
after 10mg/kg dose of D-amphetamine, but locomotion was rap-
idly suppressed, remaining at minimal levels until 110–120 min
after injection, followed by another rise in locomotion lasting
until	210 min after injection (Fig. 4C). Overall, 5-HT2CR mu-
tant mice showed less LA response to D-amphetamine.
The transient decrease in D-amphetamine-induced LA has
been proposed to result from an increase in focused stereotypies
(Yates et al., 2007). Our data indicate that the expression of these
stereotypies may be enhanced in 5-HT2CR mutant mice. To test
this hypothesis, wemeasuredmotor stereotypy in response to 2.5, 5,
and 10 mg/kg D-amphetamine in wild-type and 5-HT2CR mutant
mice. After 2.5 mg/kg D-amphetamine, there were no significant
phenotypic differences in stereotypic activity (Fig. 4D). However,
detailedanalysisof stereotypicbehaviors revealed that5-HT2CRmu-
tantmice spent significantlymore time in rearingand jumping (sup-
plemental Fig. 1, available at www.jneurosci.org as supplemental
material). Following 5 mg/kg D-amphetamine, 5-HT2CR mutant
mice spent significantly more time in total stereotypy than did wild
type (Fig. 4E). At the highest dose of 10 mg/kg, mice were almost
fully engaged in orofacial stereotypy, but there was no significant
phenotypic difference (Fig. 4F).
5-HT2CRmutant mice demonstrate increased stereotypic
behaviors following selective DAT blockade
We then examined stereotypic behavioral responses to the
selective DAT antagonist GBR 12909 (Heikkila and Manzino,
1984) in 5-HT2CR mutant and wild-type mice. We used a
modified Creese-Iversen scale to score stereotyped behaviors
in wild-type and 5-HT2CR mutant mice treated with GBR
12909 (Fig. 5A). We also examined the impact of 5-HT2CR
pharmacological blockade (using SB 206553) on stereotypic
behavioral responses to GBR 12909 (Fig. 5B). 5-HT2CR mu-
tant mice displayed increased stereotypic behaviors in re-
sponse to intermediate doses of GBR 12909. Similarly, mice
receiving both SB 206553 and intermediate doses of GBR
12909 displayed greater stereotypic behaviors compared with
wild-type mice receiving GBR 12909.
No phenotypic difference in striatal DA release after D-
amphetamine or selective DAT blockade
Given the phenotypic differences we observed in locomotor ac-
tivity and stereotypy following psychostimulant administration,
we hypothesized that we would find phenotypic differences in
psychostimulant-evoked DSt dopamine extracellular concentra-
tions. We examined dopamine release in the DSt of 5-HT2CR mu-
tant and wild-type mice in response to 2.5 and 5 mg/kg
D-amphetamine (Fig. 6A,B). A dose of 2.5 mg/kg D-amphetamine
induced a sharp increase in DA release, which peaked 40 min after
the injection (883.7 114.13 and 731 92.7% increase for wild-
type and 5-HT2CR mutant mice respectively, NS). Similarly, a 5
mg/kg D-amphetamine dose induced a sharp increase in DA re-
lease, which peaked 40 min after injection (1072.35 140.3 and
1242.6  190.7% increases in wild-type and 5-HT2CR mutant
mice respectively, NS). However, neither genotype nor any of its
relevant interactions were found to be significant by repeated-
measures ANOVA. Thus, we were unable to detect any pheno-
typic differences in D-amphetamine-evokedDSt extracellular do-
pamine concentrations.
We then examined dopamine release in the DSt of 5-HT2CR
mutant and wild-type mice in response to 3 and 10 mg/kg GBR
Figure 2. 5-HT2CRmutantmice display elevated striatal extracellular dopamine levels.A,B,
No net flux plots in DSt (A) and NAc (B) of DA from 5-HT2CR mutant and wild-type mice. The
y-axis indicates DA concentration differences between aCSF entering the probe (Cin) and aCSF
exiting the probe (Cout). The point of no net flux ( y 0 nM; horizontal dotted line) corresponds
to DA equilibriumbetween tissue andmicrodialysis probe revealing extracellular DA concentra-
tion (arrows). Estimates of in vivo DA recovery in the DSt, as indicated by the slope of the no net
flux curve, did not differ between 5-HT2CR mutant mice (0.32 0.03) and wild types (0.45
0.07, F(1,14) 3.537, NS). Similarly, estimates of in vivo DA recovery in the NAc did not differ
between groups (5-HT2CRmutantmice, 0.29 0.04; wild types, 0.34 0.03, F(1,14) 0.881,
NS). C, 5-HT2CR mutant mice display elevated mean basal dopamine concentration in the DSt
(17 2.1 nM vs 9.6 1.6 nM in wild types, F(1,15) 8.924, p 0.01) and NAc (8.5 0.7 nM
vs 6.30.8 nM inwild types, F(1,15)4.887,p0.05). Data are represented asmean SEM.
n 8 per genotype. *p 0.05; **p 0.01.
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12909 administration (Fig. 6C,D). We observed an overall in-
crease in DSt extracellular dopamine concentration following
drug administration. However, neither genotype nor any geno-
type interactions were found to be significant by repeated-
measures ANOVA. Thus, we observe that differences in locomo-
tor and stereotypical behavior following psychostimulant
administration are not accompanied by phenotypic differences in
DSt extracellular dopamine concentrations.
5-HT2CRmutant mice display enhanced D1 receptor
agonist-induced stereotypy
The above findings suggest that 5-HT2CRs influence behavioral
responses to dopamine release. This raises the possibility that
5-HT2CR mutant mice have enhanced behavioral responses to
DA receptor activation. Figure 7 displays LA in response to 10
mg/kg injection of the D1 receptor agonist SKF 81297. SKF 81297
increased LA in both wild-type and 5-HT2CR mutant mice rela-
tive to saline-injected controls. However, the magnitude of the
increase was diminished in 5-HT2CR mutant mice. Stereotypy
observed during these trials was mainly orofacial in nature, with
5-HT2CR mutant mice displaying a robust enhancement of ste-
reotypy relative to the wild-type mice (mutant mice spent
86.91  6.92% time in focused stereotypy compared with
21.29  6.18 for wild-type mice, F(1,6)  49.98, p  0.001). We
further examined the effect of quinpirole (0.6, 2, and 6mg/kg) on
LA and stereotypy. Quinpirole treatment evoked no phenotypic
effects on LA or stereotypy.
Absence of phenotypic difference in striatal D1 and D2
receptor binding
The enhanced responses of 5-HT2CRmutant mice to D1 receptor
stimulation may reflect a phenotypic difference in D1 receptor
expression. To test this hypothesis, 3H receptor-ligand-binding
autoradiographywas used to assessD1 andD2 receptor binding in
DSt and NAc. No phenotypic differences in receptor binding in
DSt and NAc were observed in either of these regions when com-
paring wild-type to 5-HT2CR mutant mice (supplemental Fig. 2,
available at www.jneurosci.org as supplemental material).
Absence of phenotypic difference in D1
receptor activation of DSt MSNs
Brain sliceswere used to examine the firing
properties of DSt MSNs. Neurons were
brought to approximately80mVby pas-
sage of DC current via the patch amplifier,
and then a series of 300 ms current pulses
was delivered every 30 s. Dopamine, acting
via the D1 receptor, can enhance action
potential firing in the DSt (Surmeier et al.,
1995; Herna´ndez-Lo´pez et al., 1997). In
agreement, the selective D1 receptor ago-
nist SKF 81297 dose-dependently en-
hanced firing in wild-type and 5-HT2CR
mutant mice, with significant enhance-
ment of action potential generation at 10
M (supplemental Fig. 3A, available at
www.jneurosci.org as supplemental mate-
rial) but not 3 M (supplemental Fig. 3C,
available at www.jneurosci.org as supple-
mental material). However, there were no
phenotypic differences in firing enhance-
ment. SKF 81297 did not alter the input
resistance, measured using a 33.3 pA hy-
perpolarizing pulse, suggesting that there was no effect of D1
receptor activation on inwardly rectifying potassium channels
(supplemental Fig. 3B,D, available at www.jneurosci.org as sup-
plemental material). Finally, as shown in supplemental Table 1
(available at www.jneurosci.org as supplemental material), there
were no differences in a number of basic firing parameters related
to action potential waveform and input resistance (n  14 cells
from six wild-type mice, n  14 cells from five 5-HT2CR mice),
suggesting that 5-HT2CR deletion did not alter the basal function
of several channels active during firing.
Discussion
These studies suggest that 5-HT2CRs have a significant role in
controlling nigrostriatal physiology and behavior. We demon-
strate that 5-HT2CR loss increases SNc dopaminergic neuron fir-
ing rates and DSt extracellular dopamine concentrations and en-
hances behaviors associatedwithDSt activation. Loss of 5-HT2CR
function enhances psychostimulant-induced stereotypy. This en-
hancement occurs without phenotypic differences in the eleva-
tion of psychostimulant-induced striatal extracellular dopamine
concentrations. Thus, loss of 5-HT2CR function may be accom-
panied by enhanced behavioral responses to released dopamine.
Phenotypic differences in stereotypic behavior following selective
D1 receptor agonist stimulation support this hypothesis. These
differences were not attributable to increases in DSt D1 receptor
expression orMSN response to dopaminergic stimulation. Thus,
these findings suggest that 5-HT2CRs inhibit behaviors associated
with nigrostriatal function at multiple loci.
5-HT2CR loss evokes a tonic activation of nigrostriatal
dopaminergic neurotransmission
In mice lacking 5-HT2CRs, SNc dopaminergic neurons displayed
elevated tonic firing rates and an increased percentage of burst-
firing cells. 5-HT2CRs are expressed onGABAergic neuronal sub-
populations (Di Giovanni et al., 2001) of the SNc [by in situ
hybridization (Eberle-Wang et al., 1997)] andVTA [by immuno-
cytochemistry (Bubar and Cunningham, 2007)]. Thus, loss of
5-HT2CR-evoked activity within these GABAergic cells could di-
minish inhibitory drive onto SNc neurons. This is consistent with
Figure 3. 5-HT2CR mutant mice exhibit altered syntactic grooming chains. A, Increased duration of phase 3 and decreased
duration of phase 4 syntactic grooming in 5-HT2CR mutant mice. Mean phase 3 duration was 29.8 2.2 s in wild-type mice,
39.8 5 s in 5-HT2CRmutantmice ( p 0.05); mean phase 4 durationwas 239.2 17.9 s in wild-typemice, 192.0 14.2 s in
5-HT2CR mutant mice ( p 0.03). B, Alteration of nonsyntactic grooming properties in 5-HT2CR mutant mice. 5-HT2CR mutant
mice exhibit increased nonsyntactic grooming event initiation (5.20 0.4 grooming events per minute vs 4.07 0.16 in wild
types; p 0.015) and reduced nonsyntactic grooming duration (1.89 0.1 vs 2.55 0.11 s inwild types, p 0.0007). Data are
represented as mean SEM. n 8 per genotype. *p 0.05; **p 0.001.
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pharmacological studies suggesting that
5-HT2CRs suppress SNc neuronal firing
[Di Giovanni et al. (1999) and Porras et al.
(2002), using SB-206553] and burst firing
[Blackburn et al. (2006), using
SB-200646A].
Surprisingly, our data demonstrate that
the htr2c null mutation has a greater im-
pact on SNc cell firing rate and bursting
properties than on those of VTA dopami-
nergic neurons. Previous studies clearly
demonstrate that pharmacological
5-HT2CR activation/inhibition evokes a
corresponding inhibition/activation of
VTA neuronal firing (Di Giovanni et al.,
1999, 2000; Di Matteo et al., 1999, 2000);
(for review, see Giorgetti and Tecott,
2004). Many of these studies suggest that
systemic modulation of 5-HT2CR activity
alters VTA neuronal activity to a greater
extent than SNcneuronal activity (DiMat-
teo et al., 2001, 2002a; Blackburn et al.,
2002). However, a number of factors com-
plicate this interpretation. Studies that use
different 5-HT2CR antagonists have
yielded disparate results. For example,
previous reports suggest that 5-HT2CR an-
tagonism increases (Di Giovanni et al.,
1999) or has no effect on (Di Matteo et al.,
1999) SNc dopaminergic neuronal firing
rates. Some of these issues may relate to
differences in the extent to which antagonist
compounds block 5-HT2CR constitutive ac-
tivity (De Deurwaerde`re et al., 2004).
Increases in SNc neuron firing rate and
burstingwere accompanied by increases in
extracellular DSt dopamine concentration
as determined by no net flux methods.
This finding is also concordant with previ-
ous studies demonstrating increased stria-
tal dopamine concentrations following
treatment with 5-HT2CR antagonists (Na-
vailles et al., 2004). Conversely, extracellu-
lar striatal dopamine concentrations were
decreased after systemic 5-HT2CR ago-
nism (Di Matteo et al., 2004). Moreover,
constitutive 5-HT2CR activity in absence
of bound ligand has been proposed to de-
crease striatal dopamine concentrations
(De Deurwaerde`re et al., 2004).
In accord with the observed changes in
baseline SNc neuronal firing properties and
DSt extracellular DA concentrations, we ob-
served altered grooming behavior in
5-HT2CR mutant mice. Increases in total
grooming have previously been observed
following treatment with dopamine D1 re-
ceptor agonists (Berridge and Aldridge,
2000)and inmiceexpressingahypoactivedopaminereuptake trans-
porter (Berridge et al., 2005). Like 5-HT2CRmutantmice, the dopa-
mine reuptake transporter hypomorphic mice displayed elevated
nonsyntactic grooming event rates. 5-HT2CR mutant mice also
demonstrate a dysregulation of syntactic grooming, a behavior spe-
cifically linked to DSt function (Cromwell and Berridge, 1996; Al-
dridge and Berridge, 1998; Aldridge et al., 2004). Similar to what is
observed followingD1 receptor agonist treatment, 5-HT2CRmutant
mice spend less time in the final phase (phase 4) of syntactic groom-
ing chains compared with wild-type mice (Matell et al., 2006). Al-
Figure 4. 5-HT2CR mutant mice display altered motor responses to D-amphetamine. E, D-Amphetamine-treated wild-type
mice; F, D-amphetamine-treated 5-HT2CR mutant mice;, saline-treated wild-type mice; f, saline-treated 5-HT2CR mutant
mice. A, Locomotor activity following 2.5 mg/kg D-amphetamine. Repeated-measures ANOVA on locomotor distance traveled
between 0 and 90 min after injection revealed significant effects of treatment (F(1,27) 131.14; p 0.001) and treatment
time interaction (F(1,27) 11.69; p 0.01). Inset, ANOVA conducted on peak activity showed significant effects of treatment
(F(1,26) 175.69; p 0.001) and treatment genotype interaction (F(1,26) 5.79; p 0.05).B, Locomotor activity following
5 mg/kg D-amphetamine. Repeated-measures ANOVA on locomotor distance traveled between 0 and 90 min after injection
revealed significant effects of time (F(1,26) 9.24; p 0.01), treatment (F(1,26) 301.19; p 0.001), and treatment
genotype interaction (F(1,26)6.94;p0.05). Inset, ANOVA conducted onpeak activity showeda significant effect of treatment
(F(1,26) 196.26; p 0.001). C, Locomotor activity following 10 mg/kg D-amphetamine. Repeated-measures ANOVA on loco-
motor distance traveled between 0 and 90min after injection showed significant effects of genotype (F(1,26) 6.04, p 0.05),
treatment (F(1,26)41.31,p0.001), and time (F(1,26)215.61,p0.001), aswell as interactionsof timegenotype (F(1,26)
 4.93; p 0.05), treatment genotype (F(1,26) 12.85; p 0.01), and time treatment (F(1,26) 47.82; p 0.001). The
tertiary interaction of time treatmentgenotypewas also significant (F(1,26)10.25;p0.01). Inset, ANOVA conductedon
peakactivity showedsignificant effects of treatment (F(1,26)63.44;p0.001) and treatmentgenotype (F(1,26)5.76;p
0.05). D, Repeated-measures ANOVA conducted on percentage time spent in stereotypy following 2.5 mg/kg D-amphetamine
revealed no significant phenotypic differences. E, 5-HT2CR mutant mice display greater focused stereotypy following 5 mg/kg
D-amphetamine (F(1,11)  5.14, p  0.05). F, No phenotypic difference in focused stereotypy following 10 mg/kg
D-amphetamine. Data are represented as mean SEM. n 7–8 per genotype per treatment.
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though these findings are consistent with an enhancement of nigro-
striatal dopamine system activity, it is also possible that the absence
of 5-HT2CRs from basal ganglia structures could contribute to the
observed grooming phenotypes.
5-HT2CR loss enhances psychostimulant-induced
motor activity
Both locomotor stereotypies and focused stereotypies (such as
grooming and gnawing) are prominent behaviors associatedwith
psychostimulants. Typically, locomotor stereotypic behaviors are
observed at lower psychostimulant doses, while focused stereotypies
predominate with higher psychostimulant doses. In 5-HT2CR mu-
tant mice, focused stereotypies were the prevalent behavior fol-
lowing D-amphetamine treatment. In contrast, locomotor ste-
reotypies were more prevalent in wild-type mice except at the
highest tested D-amphetamine dosage. In
mutant mice, behavioral responses were
characterized by greater duration of fo-
cused stereotypy and greater sensitivity to
focused stereotypy. Because
D-amphetamine nonspecifically influ-
ences monoamine release and uptake, we
examined the consequences of selective
DA transporter blockade using GBR
12909. Similarly, focused stereotypies were
observed more frequently in 5-HT2CR mu-
tant mice than in wild-type littermates fol-
lowing GBR 12909 treatment.
Unexpectedly, we did not observe phe-
notypic differences in DSt extracellular
dopamine concentrations following ad-
ministration of either GBR 12909 or
D-amphetamine. Nevertheless, we observed
enhanced focused stereotypies in 5-HT2CR
mutantmice. The finding of phenotypic dif-
ferences in psychostimulant-evoked nigro-
striatal behaviors in the absence of differ-
ences in nigrostriatal extracellular dopamine
concentration raised the possibility that be-
havioral responses to released dopamine are
enhanced by the htr2cmutation.
5-HT2CR loss enhances behavioral
sensitivity to D1 receptor activation
Phenotypic differences in the response to
dopamine release could occur through
changes within signaling pathways acti-
vated by D1-like and/or D2-like receptors.
5-HT2CR mutant mice demonstrated en-
hanced sensitivity to the behavioral effects
of the D1 receptor agonist SKF 81297,
while no phenotypic differences were
noted in behavioral responses to the D2
receptor agonist quinpirole. Thus, D1 re-
ceptor signaling pathways may contribute
substantially to the enhanced behavioral
responses of 5-HT2CR mutant mice to
psychostimulants.
In light of these findings and the known
expression of 5-HT2CRs within the DSt
(Alex et al., 2005), we evaluated D1 recep-
tor expression and function in wild-type
and mutant mice. We found no pheno-
typic difference in DSt D1 receptor expression by autoradiogra-
phy.We then examined DStMSN responses to D1 receptor stim-
ulation. Electrophysiological studies revealed enhancement of
firing after D1 receptor activation, as has been described
(Herna´ndez-Lo´pez et al., 1997). However, no significant pheno-
typic differences in the D1 receptor firing enhancement were
noted. Additionally, we did not observe gross phenotypic differ-
ences in MSN action potential waveform or other basic parame-
ters. Thus, we did not detect significant phenotypic differences in
intrinsic striatal function.
Within the basal ganglia, information from the “direct” [con-
sisting of striatal to substantia nigra reticulata/globus pallidus
interna (SNr/GPi) projections] and “indirect” [consisting of stri-
atal to globus pallidus externa (GPe) to subthalamic nucleus
(STN) projections] pathways is integrated to produce an inhibi-
Figure 5. Enhanced sensitivity of 5-HT2CR mutant mice to induction of motor stereotypy by dopamine reuptake blockade. A,
Increased GBR 12909-evoked stereotypy observed in 5-HT2CRmutantmice comparedwithwild types (F(3,56) 4.017, p 0.012
for genotype dose interaction). Behavior evaluated 90min after drug administration. B, Increased GBR 12909-evoked stereo-
typy observed in C57BL/6Jmice following treatment with the 5-HT2CR inverse agonist SB 206553 (F(3,55) 3.764, p 0.016 for
SB 206553 GBR 12909 dose interaction). In animals receiving both GBR 12909 and SB 206553, drugs were administered
simultaneously. Behavior evaluated 90min after drug administration. Data are represented asmean SEM. n 7 per genotype
per treatment.
Figure 6. No phenotypic effect on DSt extracellular dopamine concentrations after treatment with D-amphetamine or GBR
12909.E, Wild-typemice;F, 5-HT2CRmutantmice.A–D, DSt extracellular dopamine following D-amphetamine 2.5mg/kg (A),
D-amphetamine 5 mg/kg (B), GBR 12909 3 mg/kg (C), and GBR 12909 10 mg/kg (D). For A–D, no phenotypic differences were
noted between drug- and vehicle-treated groups. Arrows indicate the time of drug administration. Data are represented as
mean SEM. n 5–8 per genotype per treatment.
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tory output that is fed back to thalamocortical motor centers
(Graybiel, 2004). In addition to its expression in the SNc andDSt
components of these circuits, 5-HT2CRs are highly expressed in
the STN and SNr/GPi (Pompeiano et al., 1994; Wright et al.,
1995; Eberle-Wang et al., 1997). Serotonin applied to STN neu-
rons in slice preparations evokes a large inward current that can
be blocked by 5-HT2CR antagonists (Shen et al., 2007). This is
accompanied by increases in cell firing (Fox et al., 1998; Stanford
et al., 2005; Invernizzi et al., 2007; Shen et al., 2007). Further-
more, serotonin applied to SNr neurons in slice preparations
evokes an excitatory inward current that is blocked by 5-HT2CR
antagonists (Stanford and Lacey, 1996). Therefore, decreases in
5-HT2CR function could decrease SNr activity. The extent to
which functional perturbations within the STN and GPi contrib-
ute to the phenotypic abnormalities observed here warrants fur-
ther investigation.
We conclude that 5-HT2CRs have a substantial role control-
ling the nigrostriatal dopaminergic system and the behaviors it
regulates. Previous studies have already shown that 5-HT2CRs
have a role in mesoaccumbal dopaminergic system physiology.
5-HT2CRs are thus key regulators of the two major CNS ascend-
ing dopaminergic systems, and may play an important role inte-
grating serotonergic and dopaminergic signaling. 5-HT2CRs may
thus prove to be a clinically relevant target for the development of
drugs to treatCNSdisorders inwhich dopaminergic systems have
been implicated (Di Matteo et al., 1999), including schizophre-
nia, substance abuse, attention-deficit/hyperactivity disorder,
Parkinson’s disease, and drug-induced movement disorders.
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